NIH TRND program: successes in preclinical therapeutic development

The NIH Anticonvulsant Drug Development (ADD) Program: preclinical anticonvulsant screening project

reports are written for those compounds that have undergone multilevel evaluations. A report analyzes and interprets the generated data, and also compares the candidate compound's pharmacodynamic and pharmacokinetic profile to that of current clinically effective drugs. Annually, approximately ten promising compounds are considered for further development by the ADD Program. If a compound appea...

Failures and successes in a stroke program.

Failures and Successes in a Stroke Program • The activities toward stroke prevention and improving stroke care at Good Samaritan Hospital and Medical Center of Portland, Oregon, for the past ten years are described. The program was multifaceted and included a stroke clinic, a stroke care unit, a course for nurses from throughout the state of Oregon and southwestern Washington, panel discussions...

The NIH training grant program. A program in trouble?

Integrins as Therapeutic Targets: Successes and Cancers

Integrins are transmembrane receptors that are central to the biology of many human pathologies. Classically mediating cell-extracellular matrix and cell-cell interaction, and with an emerging role as local activators of TGFβ, they influence cancer, fibrosis, thrombosis and inflammation. Their ligand binding and some regulatory sites are extracellular and sensitive to pharmacological interventi...

Non-invasive molecular imaging for preclinical cancer therapeutic development.

Molecular and non-invasive imaging are rapidly emerging fields in preclinical cancer drug discovery. This is driven by the need to develop more efficacious and safer treatments, the advent of molecular-targeted therapeutics, and the requirements to reduce and refine current preclinical in vivo models. Such bioimaging strategies include MRI, PET, single positron emission computed tomography, ult...